ClinicalTrials.gg
CompletedNCT05551364Updated Sep 27, 2024

Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy

An interventional study of ATLAS 2030 exoskeleton in Cerebral Palsy, sponsored by MarsiBionics. Completed at 6 sites in Spain. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by MarsiBionics · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
3 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Cerebral Palsy with a site in Spain — 14 open to participants now, 17 under way, 1 of them phase 3. Cerebral Palsy · Spain.

Enrollment
23rd of 44
30 · median 32
Started
2022
with 5 others
No phase
37 of 54
11 open now
Registered
27th of 54
by date
Lead sponsor
8 of 54
MarsiBionics

Among the 54 studies in Cerebral Palsy with a site in Spain, this one is the 23rd largest by enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2022, is one of 37 with no phase, and was the 27th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

14 of the 54 studies in Cerebral Palsy with a site in Spain are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 3 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Cerebral Palsy with a site in Spain, or all of them as a file.
02

Study summary

The main objective of this study is to assess the usability and efficacy of receiving therapy with the peaditric exoskeleton ATLAS 2030in children with gait impairment due to a cerebral palsy condition. It will be valued the impact of rehabilitation with the exoskeleton at the physical level on parameters such as joint range, spasticity, as well as the impact in quality of life. It is also assessed the impact at the level of functionality of the participants, through the administration of different functional assessment scales.

03

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • exoskeleton
  • paediatric
  • gait
  • robotic gait assited training
04

Who can participate

Ages eligible
3 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical authorization to for standing, gait training and weight bearing.
  • Maximum user weight of 35 kg.
  • Length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 24cm to 33cm.
  • Tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 23cm to 32cm.
  • Hip width (between greater trochanteres) less than or equal to 35 cm.
  • Do not have an allergy to any of the ATLAS materials: cotton, nylon, polyester, polyamide, polyethylene or propylene.
  • Ability to achieve the neutral position of the ankle, during the use of the device with or without technical aids.
  • signed by legal guardians.
  • Confirmed diagnosis of cerebral palsy affecting the ability to walk.
  • Stable medical condition without modifications of the specific medication for the disease in the last 6 months, and other additional medication in the last month.
  • Patient in follow-up according to the normal standards recommended for his illness.

Exclusion criteria

Exclusion Criteria:

  • More than 20º of hip flessum at the time of using the exoskeleton.
  • More than 20º of knee flessum at the time of using the exoskeleton.
  • Severe skin lesion on parts of the lower extremities that are in contact with the device.
  • Scheduled surgery (rachis, limbs) for the duration of the study or surgery performed (rachis, extremities) in the last 6 months.
  • History of fracture without trauma. History of bone fracture traumatic in lower extremities or pelvic girdle in the last 3 months.
  • Refusal of the patient or legal guardian to include the child in the study.
  • Skin problems (diseases, allergies, sensitivity ...) that prevent the use of exoskeleton accessories on the patient's skin.
  • Spasticity equal to 4 on the Modified Ashworth Scale at the time of use of the device.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • No intervention
    Conventional Treatment

    The children will continue with their current rehabilitation program

  • Experimental
    Treatment with the ATLAS 2030 Exoskeleton

    The children will receive 2 hours of exoskeleton ATLAS 2030 gait training a week for 3 months

    Device: ATLAS 2030 exoskeleton

Interventions

  • DeviceATLAS 2030 exoskeleton

    Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases: 1. Telephone contact phase (1 session) 2. Inclusion Phase (1 session) 3. Signing of informed consent (1 session) 4. Initial Evaluation Phase (1 session) 5. Treatment Phase (1st part) (7 sessions) 6. Monthly Evaluation Phase (1 session) 7. Treatment Phase (2nd part) (7 sessions) 8. Monthly Evaluation Phase (1 session) 9. Treatment Phase (3rd part) (7 sessions) 10. Final Evaluation Phase and results (2 sessions)

06

What researchers measure

Primary outcomes

  1. Gross Motor Function Classification System

    To indentify the diffrent levels of the Gross Motor Function Classification System who can use the ATLAS 2030 exoskeleton. The Gross Motor Function Classification System goes from Level 1 (can walk indoors and outdoors and climb stairs without using hands for support; can perform usual activities such as running and jumping; has decreased speed, balance and coordination) to Level 5 (has physical impairments that restrict voluntary control of movement and the ability to maintain head and neck position against gravity; is impaired in all areas of motor function; cannot sit or stand independently, even with adaptive equipment; cannot independently walk, though may be able to use powered mobility)

    Time frame: Every month up to 3 months

  2. To quantify number of steps taken within the device

    Quantity of steps taken within the exoskeleton

    Time frame: Every session up to 28 sessions

  3. Changes in joint range of motion

    To evaluate the joint range of motion changes at the hip, knee and ankle after the ATLAS 2030 use measured by goniometer

    Time frame: Every session up to 28 sessions

  4. Changes in spasticity

    To evaluate spasticity changes at the lower limb muscle groups after ATLAS 2030 use by Modified Asworth Scale

    Time frame: Every session up to 28 sessions

  5. Changes in the Six-Minute Walking Test performance

    To assess changes in the distance the child can walk in six minutes by using the Six-Minute Walking Test

    Time frame: Every month up to three months

  6. Changes in the 10 Meters Walking Test performance

    To assess changes in the time needed to walk 10 meters by using the 10 Meters Walking Test

    Time frame: Every month up to three months

  7. Changes in the time walked within the device

    To assess possible changes in the time walked within the device

    Time frame: Three months

  8. Changes in the Gross Motor Function Measure 88 for children with cerebral palsy (GMFM-88)

    To evaluate possible changes in the gross motor function after 3 months of ATLAS 2030 use twice a week where a higher score means child´s gross motor function is better

    Time frame: Every month up to three months

  9. Changes in the Functional Independence Measure for Children (WeeFim)

    To evaluate possible changes in the overall functionality after 3 months of ATLAS 2030 use twice a week by using the Functional Independence Measure for Children where a higher score means the child is more functional, more independant

    Time frame: Every month up to three months

  10. Cerebral Palsy Quality of Life

    To assess possible changes in the quality of life of the children after using the ATLAS 2030 for 3 months twice a week by using the Cerebral Palsy Quallity of Life scale where a higher percentage means a better quality of life

    Time frame: Three months

Secondary outcomes

  1. Safety of the ATLAS 2030

    Measured as the occurrence of adverse events such as onset of pain, fatigue, presence of falls or alteration of the integrity of the user's skin, by the use of the device.

    Time frame: at study completion

  2. The Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)

    To assess both professionals and patients´satisfaction when using the ATLAS 2030

    Time frame: at study completion

  3. Acceptability

    Measured through the dropout rate of the participants.

    Time frame: at study completion

  4. Accessibility

    Measure such as the relationship between the number of patients recruited and potential patients who were not recruited

    Time frame: at study completion

07

Study locations

6 sites
  • Colegio de Educación Especial San Martín de Porres (ATADES)
    Zaragoza, Aragón 35012, Spain
  • ATENPACE
    Madrid, Spain
  • Centre for Automation and Robotics, Marsi Care
    Madrid, Spain
  • Fundación Bobath
    Madrid, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, Spain
  • Universidad de Zaragoza
    Zaragoza, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jun 2023, 8 months.

Of 925 interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2022
First posted
Sep 22, 2022
StartActual
Sep 5, 2022
Primary completionActual
Jun 2, 2023
CompletionActual
Aug 30, 2023
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05551364
Lead sponsor
MarsiBionics
Collaborators
Hospital Miguel Servet, ATADES, Universidad de Zaragoza, Spanish National Research Council, Fundación Bobath Madrid, ATENPACE Madrid
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Sep 5, 2022
Primary completion
Jun 2, 2023
Completion
Aug 30, 2023
Last update
Sep 27, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion